Company profile: Veracyte
1.1 - Company Overview
Company description
- Provider of molecular diagnostic tests to improve patient outcomes and lower healthcare costs, including genomic classifiers: Afirma for thyroid cancer (RNA sequencing), Decipher Prostate for aggressiveness/metastasis risk, Envisia for differentiating IPF, Prosigna for early breast cancer recurrence risk, and Decipher Bladder to inform treatment.
Products and services
- Prosigna Breast Cancer Assay: A 50-gene-signature-based genomic test for early-stage breast cancer that delivers a risk of recurrence score by analyzing the activity of a 50-gene signature
- Afirma Genomic Sequencing Classifier: An RNA-sequencing-based test for thyroid cancer diagnosis that identifies patients without cancer and informs treatment decisions using genomic analysis
- Decipher Prostate Genomic Classifier: A genomic-classifier-based test for prostate cancer that assesses cancer aggressiveness and metastasis likelihood to guide treatment planning
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Veracyte
Idenix
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development focused on discovering and developing drugs to treat human viral diseases, with an emphasis on hepatitis C virus (HCV), with operations in the United States and Europe.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Idenix company profile →
Celsius Therapeutics
HQ: United States
Website
- Description: Provider of precision medicines for cancer and autoimmune diseases, leveraging single-cell genomics and machine learning to identify therapeutic targets. Offerings include CEL383, an anti-TREM1 antibody in Phase 1 for inflammatory bowel disease, the SCOPE platform for single-cell RNA sequencing–driven analysis, and oncology drug discovery programs based on single-cell tumor analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celsius Therapeutics company profile →
CDx Diagnostics
HQ: United States
Website
- Description: Provider of cancer-prevention diagnostic systems that detect pre-cancerous cells, including WATS3D, combining wide-area tissue sampling, 3D imaging, AI analysis, and GI pathologist review for Barrett’s esophagus and dysplasia; OralCDx, a non-invasive oral brush biopsy with AI-enabled tissue analysis; and laboratory cytopathology and histopathology services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CDx Diagnostics company profile →
Elucigene
HQ: United Kingdom
Website
- Description: Provider of clinical diagnostic assays and product realisation services, offering kits for cystic fibrosis (CFTR mutations), rapid aneuploidy analysis (QF-PCR for trisomies 21, 18, 13 and sex chromosome aneuploidies), reproductive health (recurrent miscarriage, male infertility, Y-microdeletion), and genetic disease diagnosis (thrombophilia, alpha-1-antitrypsin). Services include assay development, validation, manufacturing, regulatory strategy, and commercial sale and distribution.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elucigene company profile →
ActX
HQ: United States
Website
- Description: Provider of genomic screening and pharmacogenomic services that help physicians personalize prescriptions, identify hereditary risks, understand carrier status, and adjust dosing based on drug-genome interactions. Offers GenoACT clinical decision support integrating genetic data into EHRs with real-time alerts, plus medical genetic interpretation of 23andMe raw data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ActX company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Veracyte
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Veracyte
2.2 - Growth funds investing in similar companies to Veracyte
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Veracyte
4.2 - Public trading comparable groups for Veracyte
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →